<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02859948</url>
  </required_header>
  <id_info>
    <org_study_id>1028201601/PRO</org_study_id>
    <nct_id>NCT02859948</nct_id>
  </id_info>
  <brief_title>A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SKLB1028 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will receive oral SKLB1028 for 28 days to study the side effects, tolerability and&#xD;
      best dose for treating relapsed or refractory acute myeloid leukemia With FLT3 Mutations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is open-label, dose escalation study designed to characterize the safety, tolerability,&#xD;
      pharmacokinetics (PK) and pharmacodynamics (PD) of orally administered SKLB1028 as a single&#xD;
      agent given daily for 28 days. Cohorts of 3 patients receive SKLB1028 until dose limiting&#xD;
      toxicity is noted (DLT). At that point cohorts will expand to 6 patients until MTD is&#xD;
      determined. Patients not experiencing DLT or significant disease progression could continue&#xD;
      receiving SKLB1028 up to 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence of dose limiting toxicity (DLT)and Adverse Event (AE)</measure>
    <time_frame>28 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) from time zero to the time point of t (AUC0-tn)</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) from time zero to infinity (AUC0-inf)</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at equilibrium after oral administration（Vss/F）</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2z)</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CLz/F)</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average plasma or serum concentration(Cav)</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in FLT3 mutation status in plasma</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Remission (CR)</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of partial remission (PR)</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>SKLB1028</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SKLB1028</intervention_name>
    <description>SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.</description>
    <arm_group_label>SKLB1028</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be provided.&#xD;
&#xD;
          -  Males and females age ≥ 18 years;&#xD;
&#xD;
          -  Histopathologically documented primary or secondary AML, as defined by WHO criteria,&#xD;
             confirmed by pathology review at treating institution, meeting at least one of the&#xD;
             following:&#xD;
&#xD;
               1. Refractory to at least 1 cycle of induction chemotherapy, or&#xD;
&#xD;
               2. Relapsed after at least 1 cycle of induction chemotherapy, or&#xD;
&#xD;
               3. Patient is not, according to the clinical judgment of the Principal Investigator,&#xD;
                  a candidate for induction chemotherapy due to age, comorbidity, or other factors;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-3;&#xD;
&#xD;
          -  In the absence of rapidly progressing disease, the interval from prior treatment to&#xD;
             time of SKLB1028 administration should be at least 2 weeks for cytotoxic agents, or at&#xD;
             least 5 half-lives for noncytotoxic agents;&#xD;
&#xD;
          -  Serum creatinine ≤1.5 × ULN;&#xD;
&#xD;
          -  Total serum bilirubin ≤ 1.5 × ULN unless considered due to Gilbert's syndrome or&#xD;
             leukemic organ involvement;&#xD;
&#xD;
          -  Serum AST or ALT ≤ 3.0 × ULN unless considered due to leukemic organ involvement;&#xD;
&#xD;
          -  Females of childbearing potential and sexually mature males must agree to use a&#xD;
             medically accepted method of contraception throughout the study;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Histologic diagnosis of acute promyelocytic leukemia;&#xD;
&#xD;
          -  Clinically active central nervous system leukemia;&#xD;
&#xD;
          -  Persistent clinically significant toxicity from prior chemotherapy that is Grade 2 or&#xD;
             higher;&#xD;
&#xD;
          -  Bone marrow transplant within 100 days prior to study;&#xD;
&#xD;
          -  Active, uncontrolled infection;&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to study;&#xD;
&#xD;
          -  Radiation therapy within 4 weeks prior to study;&#xD;
&#xD;
          -  Left ventricular ejection fraction ≤1 × ULN,or﹤50%. Clinically significant ECG QTc&#xD;
             prolongation (Male: &gt;450ms, Female: &gt;470ms).Significant cardiac disease.&#xD;
&#xD;
          -  Human immunodeficiency virus positivity;&#xD;
&#xD;
          -  Active hepatitis B or C or other active liver disease;&#xD;
&#xD;
          -  Women who are pregnant, lactating;&#xD;
&#xD;
          -  Medical condition, serious intercurrent illness, or other extenuating circumstance&#xD;
             that, in the judgment of the Principal Investigator, could jeopardize patient safety&#xD;
             or interfere with the objectives of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ting Liu, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ting Liu, Dr.</last_name>
    <phone>86-028-85422364</phone>
    <email>liuting@scu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital，Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting Liu, Dr.</last_name>
      <phone>86-028-85422364</phone>
      <email>liuting@scu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>June 28, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>August 4, 2016</last_update_submitted>
  <last_update_submitted_qc>August 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

